Oncology

  • Oncology1982

    Eastern Cooperative Oncology Group (ECOG) Performance Status

    The Eastern Cooperative Oncology Group (ECOG) Performance Status is indicated for bedside clinical practice to support Determines patient's ability to tolerate therapies in severe illness, specifically for chemotherapy. Simple 5-point scale that describes patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1949_original

    Karnofsky Performance Status Scale

    The Karnofsky Performance Status Scale is indicated for bedside clinical practice to support Determines patient's ability to tolerate therapies in serious illness, specifically for chemotherapy. This validated functional status scale ranges from 100% (normal, no evidence of disease) to 0% (death) and correlates with treatment tolerance, survival, and quality of life in cancer patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology5.0

    Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic

    The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic is indicated for bedside clinical practice to support Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2008_original

    Khorana Risk Score for Venous Thromboembolism in Cancer Patients

    The Khorana Risk Score for Venous Thromboembolism in Cancer Patients is indicated for bedside clinical practice to support Predicts VTE risk for cancer patients depending on cancer type and other factors. This validated risk assessment tool helps identify cancer patients at high risk for venous thromboembolism who may benefit from thromboprophylaxis during chemotherapy treatment.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2010

    Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) is indicated for bedside clinical practice to support Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2015

    Clinical Index of Stable Febrile Neutropenia (CISNE)

    The Clinical Index of Stable Febrile Neutropenia (CISNE) is indicated for bedside clinical practice to support Identifies febrile neutropenia patients at low risk for serious complications. Used for adult outpatients with solid tumor, fever ≥38°C (100.4°F), and neutropenia (≤500 cells/mm³ or ≤1,000 cells/mm³ with expected decrease to 500).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2022

    Barcelona-Clinic Liver Cancer (BCLC) Staging Classification

    The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification is indicated for bedside clinical practice to support Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1998

    D'Amico Risk Classification for Prostate Cancer

    The D'Amico Risk Classification for Prostate Cancer is indicated for bedside clinical practice to support Assesses 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Stratifies patients into low, intermediate, or high-risk groups to guide treatment decisions and prognosis estimation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2013

    IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma

    The IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma is indicated for bedside clinical practice to support Predicts survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2015

    ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)

    The ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC) is indicated for bedside clinical practice to support Predicts survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin). It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    Gail Model for Breast Cancer Risk

    The Gail Model for Breast Cancer Risk is indicated for bedside clinical practice to support Estimates risk for breast cancer based on demographic and clinical data. The Gail Model calculates a woman's absolute risk of developing invasive breast cancer over the next 5 years and up to age 90 (lifetime risk) using personal medical and reproductive history and family history of breast cancer among first-degree relatives.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2019

    PSA Doubling Time (PSADT) Calculator

    The PSA Doubling Time (PSADT) Calculator is indicated for bedside clinical practice to support Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

    The Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts survival based on clinical and laboratory data in metastatic RCC patients. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyASTCT_2019

    Cytokine Release Syndrome (CRS) Grading

    The Cytokine Release Syndrome (CRS) Grading is indicated for bedside clinical practice to support Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1989

    Mirels' Criteria for Prophylactic Fixation

    The Mirels' Criteria for Prophylactic Fixation is indicated for bedside clinical practice to support Predicts risk of pathologic fracture in patients with long bone metastasis to guide prophylactic fixation decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyModified

    Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes

    The Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes is indicated for bedside clinical practice to support Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Immune-Related Adverse Events for GI Toxicity - Colitis

    The Immune-Related Adverse Events for GI Toxicity - Colitis is indicated for bedside clinical practice to support Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyCTCAE v5.0

    Immune-Related Adverse Events for Lung Toxicity - Pneumonitis

    The Immune-Related Adverse Events for Lung Toxicity - Pneumonitis is indicated for bedside clinical practice to support Grades severity of pneumonitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates respiratory symptoms, oxygen requirements, and functional impact to determine the severity of immune-mediated pneumonitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, pulmonology consultation needs, and monitoring for life-threatening respiratory complications. ICPi-induced pneumonitis has an incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis in single-agent therapy. The calculator provides evidence-based management recommendations essential for oncologists, pulmonologists, and intensive care teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism

    The Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism is indicated for bedside clinical practice to support Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyCTCAE v5.0

    Immune-Related Adverse Events for GI Toxicity - Hepatitis

    The Immune-Related Adverse Events for GI Toxicity - Hepatitis is indicated for bedside clinical practice to support Grades severity of hepatitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates liver function tests including AST, ALT, and total bilirubin levels to determine the severity of immune-mediated hepatitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, hepatology consultation needs, and monitoring for life-threatening complications. ICPi-induced hepatitis has an incidence of 5-10% in single-agent therapy but severe toxicity occurs in less than 2% of cases. The calculator provides evidence-based management recommendations essential for oncologists, hepatologists, and multidisciplinary teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus

    The Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus is indicated for bedside clinical practice to support Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyCTCAE v5.0

    Immune-Related Adverse Events for Renal Toxicities - Nephritis

    The Immune-Related Adverse Events for Renal Toxicities - Nephritis is indicated for bedside clinical practice to support Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2011

    Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)

    The Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT) is indicated for bedside clinical practice to support The CARG-TT estimates the risk of severe chemotherapy-related side effects (Grade 3 or greater toxicity) in older cancer patients (age >65). It uses 11 geriatric assessment variables, laboratory values, and patient characteristics to predict chemotherapy toxicity risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2012

    Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score

    The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score is indicated for bedside clinical practice to support Assesses the risk of severe chemotherapy toxicity in older cancer patients (≥70 years). Predicts both hematologic (grade 4) and nonhematologic (grade 3/4) toxicities based on patient characteristics and chemotherapy regimen.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    Fong Clinical Risk Score for Colorectal Cancer Recurrence

    The Fong Clinical Risk Score for Colorectal Cancer Recurrence is indicated for bedside clinical practice to support Predicts recurrence and survival risk for colorectal cancer patients with liver metastases after hepatic resection. Developed from analysis of 1,001 consecutive cases to identify high-risk patients who may benefit from adjuvant therapy or closer surveillance.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2016

    GALAD Model for Hepatocellular Carcinoma (HCC)

    The GALAD Model for Hepatocellular Carcinoma (HCC) is indicated for bedside clinical practice to support Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2009

    Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival

    The Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival is indicated for bedside clinical practice to support Predicts 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria. Uses tumor size, number, and vascular invasion status.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2018

    2018 Leibovich Model for Renal Cell Carcinoma (RCC)

    The 2018 Leibovich Model for Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2005

    Mekhail Extension of the Motzer Score

    The Mekhail Extension of the Motzer Score is indicated for bedside clinical practice to support Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2007

    Asymptomatic Myeloma Prognosis

    The Asymptomatic Myeloma Prognosis is indicated for bedside clinical practice to support Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncologyclive_2014

    LENT Prognostic Score for Malignant Pleural Effusion

    The LENT Prognostic Score for Malignant Pleural Effusion is indicated for bedside clinical practice to support Predicts survival in patients with malignant pleural effusion using clinical and laboratory parameters to help inform treatment decisions and prognosis discussions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2018

    PROMISE Score for Malignant Pleural Effusion

    The PROMISE Score for Malignant Pleural Effusion is indicated for bedside clinical practice to support Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2019

    Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA)

    The Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA) is indicated for bedside clinical practice to support Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2017

    Brain Metastasis Velocity (BMV) Model

    The Brain Metastasis Velocity (BMV) Model is indicated for bedside clinical practice to support Calculates rate of distant brain failure after stereotactic radiosurgery for brain metastasis to predict overall survival. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2012

    Prostate Tumor Volume & Density

    The Prostate Tumor Volume & Density is indicated for bedside clinical practice to support Calculates prostate volume using ellipsoid formula and PSA density to help distinguish between benign prostatic hyperplasia (BPH) and prostate cancer. This tool assists in biopsy decision-making, risk stratification, and treatment planning for patients with elevated PSA levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2011

    Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score

    The Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score is indicated for bedside clinical practice to support Predicts small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset. The score helps identify high-risk patients requiring intensive cancer screening.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2013

    Prognostic Index for Cancer Outcomes

    The Prognostic Index for Cancer Outcomes is indicated for bedside clinical practice to support Predicts cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. This simple two-parameter scoring system provides risk stratification for cancer patients and helps guide prognostic discussions and clinical decision-making across multiple cancer types.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2003

    Additional Nodal Metastasis Nomogram

    The Additional Nodal Metastasis Nomogram is indicated for bedside clinical practice to support Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncologystandard

    BED / EQD2

    The BED / EQD2 is indicated for bedside clinical practice to support Biologically effective dose and equivalent dose in 2-Gy fractions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1989

    Carboplatin Dose (Calvert)

    The Carboplatin Dose (Calvert) is indicated for bedside clinical practice to support Carboplatin dose by the Calvert formula.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1.0

    Chemotherapy Dose (BSA-based)

    The Chemotherapy Dose (BSA-based) is indicated for bedside clinical practice to support BSA-based chemotherapy dosing using Du Bois formula.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology5.0

    CTCAE Neutropenia Grade

    The CTCAE Neutropenia Grade is indicated for bedside clinical practice to support CTCAE neutropenia grading from the absolute neutrophil count (ANC): Grade 1 (<LLN-1500), Grade 2 (<1500-1000), Grade 3 (<1000-500), Grade 4 (<500 /mm³). Standard oncology toxicity grading for chemotherapy decisions and growth-factor support.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1998

    EBMT (Gratwohl) Transplant Risk Score

    The EBMT (Gratwohl) Transplant Risk Score is indicated for bedside clinical practice to support Pre-transplant risk score for allogeneic HSCT (0-7).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1982

    ECOG-Karnofsky Performance Status Converter

    The ECOG-Karnofsky Performance Status Converter is indicated for bedside clinical practice to support Bidirectional conversion between ECOG and Karnofsky scales.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2016

    ELTS Score (EUTOS Long-Term Survival)

    The ELTS Score (EUTOS Long-Term Survival) is indicated for bedside clinical practice to support CML long-term survival risk score.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1989

    EQD2 - Equivalent Dose in 2 Gy Fractions

    The EQD2 - Equivalent Dose in 2 Gy Fractions is indicated for bedside clinical practice to support Converts a radiotherapy schedule to equivalent dose in 2 Gy fractions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyOriginal_and_Modified

    Glasgow Prognostic Score (GPS)

    The Glasgow Prognostic Score (GPS) is indicated for bedside clinical practice to support Inflammation and nutrition-based prognostic score for cancer patients using serum C-reactive protein and albumin levels. Predicts overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2017

    iRECIST Response (Immunotherapy)

    The iRECIST Response (Immunotherapy) is indicated for bedside clinical practice to support Simplified iRECIST response classification for solid tumors on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2016

    Lung Cancer TNM Staging (8th Edition)

    The Lung Cancer TNM Staging (8th Edition) is indicated for bedside clinical practice to support IASLC 8th edition TNM stage grouping for non-small cell lung cancer.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1982

    Nottingham Prognostic Index (NPI)

    The Nottingham Prognostic Index (NPI) is indicated for bedside clinical practice to support Nottingham Prognostic Index (Haybittle 1982) for primary breast cancer: NPI = 0.2 × tumor size (cm) + lymph-node stage (1-3) + histologic grade (1-3). Bands: ≤2.4 excellent, 2.41-3.4 good, 3.41-4.4 moderate, 4.41-5.4 poor, >5.4 very poor. Implemented from the published paper (AGPL source repo not copied).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Pack-Years — Smoking Burden / Lung Screening

    The Pack-Years — Smoking Burden / Lung Screening is indicated for bedside clinical practice to support Pack-years quantify lifetime smoking exposure: (cigarettes per day / 20) x years smoked. >=20 pack-years is the USPSTF 2021 lung-cancer screening threshold (ages 50-80).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    PaP Score — Palliative Prognostic Score

    The PaP Score — Palliative Prognostic Score is indicated for bedside clinical practice to support The PaP score estimates 30-day survival probability in advanced solid-tumor patients from 6 variables (dyspnea, anorexia, KPS, clinician prediction, WBC, lymphocyte %). Total 0-17.5.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyFDA label

    Pegfilgrastim Dosing (per Label)

    The Pegfilgrastim Dosing (per Label) is indicated for bedside clinical practice to support Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologySugarbaker

    Peritoneal Cancer Index (PCI)

    The Peritoneal Cancer Index (PCI) is indicated for bedside clinical practice to support Peritoneal Cancer Index (Sugarbaker): 13 abdominopelvic regions each scored by largest lesion — LS-0 none, LS-1 <0.5 cm, LS-2 0.5-5 cm, LS-3 >5 cm or confluence; total 0-39. Higher = greater tumor burden; guides cytoreduction/HIPEC decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology

    PET Total Lesion Glycolysis (TLG)

    The PET Total Lesion Glycolysis (TLG) is indicated for bedside clinical practice to support Total lesion glycolysis: metabolic tumor volume multiplied by mean SUV. Prognostic PET metric in oncology.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2015

    R-ISS

    The R-ISS is indicated for bedside clinical practice to support Revised International Staging System for multiple myeloma.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2010

    Radiation Pneumonitis Dose Constraints

    The Radiation Pneumonitis Dose Constraints is indicated for bedside clinical practice to support QUANTEC-based lung dose constraint check: mean lung dose and V20 vs symptomatic pneumonitis risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2010

    Spinal Instability Neoplastic Score (SINS)

    The Spinal Instability Neoplastic Score (SINS) is indicated for bedside clinical practice to support Spinal Instability Neoplastic Score (SINS): quantifies spinal instability in patients with spinal metastases across 6 components (location, pain, bone lesion, alignment, vertebral collapse, posterolateral involvement). Total 0-18; higher scores indicate greater instability and need for surgical consultation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2005

    UCSF-CAPRA Prostate Cancer Risk Score

    The UCSF-CAPRA Prostate Cancer Risk Score is indicated for bedside clinical practice to support UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2003

    Additional Nodal Metastasis Nomogram

    The Additional Nodal Metastasis Nomogram is indicated for bedside clinical practice to support Predicts probability of additional non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node biopsy. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2015

    ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC)

    The ALBI (Albumin-Bilirubin) Grade for Hepatocellular Carcinoma (HCC) is indicated for bedside clinical practice to support Predicts survival in hepatocellular carcinoma patients based on objective measures of liver function (albumin and bilirubin). It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2007

    Asymptomatic Myeloma Prognosis

    The Asymptomatic Myeloma Prognosis is indicated for bedside clinical practice to support Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2022

    Barcelona-Clinic Liver Cancer (BCLC) Staging Classification

    The Barcelona-Clinic Liver Cancer (BCLC) Staging Classification is indicated for bedside clinical practice to support Determines disease progression and appropriate treatment course for hepatocellular carcinoma (HCC) patients. The BCLC staging system integrates tumor characteristics, liver function status, and performance status to classify patients into five stages (0, A, B, C, D) with specific treatment recommendations for each stage.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncologystandard

    BED / EQD2

    The BED / EQD2 is indicated for bedside clinical practice to support Biologically effective dose and equivalent dose in 2-Gy fractions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2017

    Brain Metastasis Velocity (BMV) Model

    The Brain Metastasis Velocity (BMV) Model is indicated for bedside clinical practice to support Calculates rate of distant brain failure after stereotactic radiosurgery for brain metastasis to predict overall survival. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1989

    Carboplatin Dose (Calvert)

    The Carboplatin Dose (Calvert) is indicated for bedside clinical practice to support Carboplatin dose by the Calvert formula.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2011

    Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT)

    The Cancer and Aging Research Group Chemotherapy Toxicity Tool (CARG-TT) is indicated for bedside clinical practice to support The CARG-TT estimates the risk of severe chemotherapy-related side effects (Grade 3 or greater toxicity) in older cancer patients (age >65). It uses 11 geriatric assessment variables, laboratory values, and patient characteristics to predict chemotherapy toxicity risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1.0

    Chemotherapy Dose (BSA-based)

    The Chemotherapy Dose (BSA-based) is indicated for bedside clinical practice to support BSA-based chemotherapy dosing using Du Bois formula.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2012

    Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score

    The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) Score is indicated for bedside clinical practice to support Assesses the risk of severe chemotherapy toxicity in older cancer patients (≥70 years). Predicts both hematologic (grade 4) and nonhematologic (grade 3/4) toxicities based on patient characteristics and chemotherapy regimen.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyASTCT_2019

    Cytokine Release Syndrome (CRS) Grading

    The Cytokine Release Syndrome (CRS) Grading is indicated for bedside clinical practice to support Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1998

    D'Amico Risk Classification for Prostate Cancer

    The D'Amico Risk Classification for Prostate Cancer is indicated for bedside clinical practice to support Assesses 5-year risk of treatment failure in patients with localized prostate cancer based on clinical factors. Stratifies patients into low, intermediate, or high-risk groups to guide treatment decisions and prognosis estimation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2011

    Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score

    The Dutch-English LEMS Tumor Association Prediction (DELTA-P) Score is indicated for bedside clinical practice to support Predicts small-cell lung cancer (SCLC) in patients with Lambert-Eaton myasthenic syndrome (LEMS) using clinical parameters assessed at or within 3 months of onset. The score helps identify high-risk patients requiring intensive cancer screening.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1998

    EBMT (Gratwohl) Transplant Risk Score

    The EBMT (Gratwohl) Transplant Risk Score is indicated for bedside clinical practice to support Pre-transplant risk score for allogeneic HSCT (0-7).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1982

    ECOG-Karnofsky Performance Status Converter

    The ECOG-Karnofsky Performance Status Converter is indicated for bedside clinical practice to support Bidirectional conversion between ECOG and Karnofsky scales.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1982

    Eastern Cooperative Oncology Group (ECOG) Performance Status

    The Eastern Cooperative Oncology Group (ECOG) Performance Status is indicated for bedside clinical practice to support Determines patient's ability to tolerate therapies in severe illness, specifically for chemotherapy. Simple 5-point scale that describes patient's level of functioning in terms of their ability to care for themselves, daily activity, and physical ability.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2016

    ELTS Score (EUTOS Long-Term Survival)

    The ELTS Score (EUTOS Long-Term Survival) is indicated for bedside clinical practice to support CML long-term survival risk score.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    Fong Clinical Risk Score for Colorectal Cancer Recurrence

    The Fong Clinical Risk Score for Colorectal Cancer Recurrence is indicated for bedside clinical practice to support Predicts recurrence and survival risk for colorectal cancer patients with liver metastases after hepatic resection. Developed from analysis of 1,001 consecutive cases to identify high-risk patients who may benefit from adjuvant therapy or closer surveillance.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    Gail Model for Breast Cancer Risk

    The Gail Model for Breast Cancer Risk is indicated for bedside clinical practice to support Estimates risk for breast cancer based on demographic and clinical data. The Gail Model calculates a woman's absolute risk of developing invasive breast cancer over the next 5 years and up to age 90 (lifetime risk) using personal medical and reproductive history and family history of breast cancer among first-degree relatives.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2016

    GALAD Model for Hepatocellular Carcinoma (HCC)

    The GALAD Model for Hepatocellular Carcinoma (HCC) is indicated for bedside clinical practice to support Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2019

    Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA)

    The Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA) is indicated for bedside clinical practice to support Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyOriginal_and_Modified

    Glasgow Prognostic Score (GPS)

    The Glasgow Prognostic Score (GPS) is indicated for bedside clinical practice to support Inflammation and nutrition-based prognostic score for cancer patients using serum C-reactive protein and albumin levels. Predicts overall survival and disease-free survival across multiple cancer types including colorectal, hepatocellular carcinoma, sarcoma, and lung cancer.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2013

    IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma

    The IMDC (International Metastatic RCC Database Consortium) Risk Model for Metastatic Renal Cell Carcinoma is indicated for bedside clinical practice to support Predicts survival in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapy and assists in treatment selection based on risk stratification. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus

    The Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus is indicated for bedside clinical practice to support Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism

    The Immune-Related Adverse Events for Endocrine Toxicities - Hypothyroidism is indicated for bedside clinical practice to support Grades severity of hypothyroidism secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Immune-Related Adverse Events for GI Toxicity - Colitis

    The Immune-Related Adverse Events for GI Toxicity - Colitis is indicated for bedside clinical practice to support Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyCTCAE v5.0

    Immune-Related Adverse Events for GI Toxicity - Hepatitis

    The Immune-Related Adverse Events for GI Toxicity - Hepatitis is indicated for bedside clinical practice to support Grades severity of hepatitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates liver function tests including AST, ALT, and total bilirubin levels to determine the severity of immune-mediated hepatitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, hepatology consultation needs, and monitoring for life-threatening complications. ICPi-induced hepatitis has an incidence of 5-10% in single-agent therapy but severe toxicity occurs in less than 2% of cases. The calculator provides evidence-based management recommendations essential for oncologists, hepatologists, and multidisciplinary teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyCTCAE v5.0

    Immune-Related Adverse Events for Lung Toxicity - Pneumonitis

    The Immune-Related Adverse Events for Lung Toxicity - Pneumonitis is indicated for bedside clinical practice to support Grades severity of pneumonitis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates respiratory symptoms, oxygen requirements, and functional impact to determine the severity of immune-mediated pneumonitis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, pulmonology consultation needs, and monitoring for life-threatening respiratory complications. ICPi-induced pneumonitis has an incidence of 2.7% for all-grade and 0.8% for high-grade pneumonitis in single-agent therapy. The calculator provides evidence-based management recommendations essential for oncologists, pulmonologists, and intensive care teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyCTCAE v5.0

    Immune-Related Adverse Events for Renal Toxicities - Nephritis

    The Immune-Related Adverse Events for Renal Toxicities - Nephritis is indicated for bedside clinical practice to support Grades severity of nephritis secondary to immune checkpoint inhibitor (ICPi) therapy based on Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 criteria. This standardized grading system evaluates serum creatinine levels, renal function changes, and clinical symptoms to determine the severity of immune-mediated nephritis and guide clinical management decisions including ICPi therapy continuation, corticosteroid treatment, nephrology consultation needs, and monitoring for life-threatening renal complications. ICPi-induced nephritis has an incidence of 1-2% in single-agent therapy and 4.5% in combination therapy, with median onset at 14 weeks (range 6.5-21 weeks). The calculator provides evidence-based management recommendations essential for oncologists, nephrologists, and multidisciplinary teams managing patients on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2017

    iRECIST Response (Immunotherapy)

    The iRECIST Response (Immunotherapy) is indicated for bedside clinical practice to support Simplified iRECIST response classification for solid tumors on immunotherapy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1949_original

    Karnofsky Performance Status Scale

    The Karnofsky Performance Status Scale is indicated for bedside clinical practice to support Determines patient's ability to tolerate therapies in serious illness, specifically for chemotherapy. This validated functional status scale ranges from 100% (normal, no evidence of disease) to 0% (death) and correlates with treatment tolerance, survival, and quality of life in cancer patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2008_original

    Khorana Risk Score for Venous Thromboembolism in Cancer Patients

    The Khorana Risk Score for Venous Thromboembolism in Cancer Patients is indicated for bedside clinical practice to support Predicts VTE risk for cancer patients depending on cancer type and other factors. This validated risk assessment tool helps identify cancer patients at high risk for venous thromboembolism who may benefit from thromboprophylaxis during chemotherapy treatment.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2018

    2018 Leibovich Model for Renal Cell Carcinoma (RCC)

    The 2018 Leibovich Model for Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts progression-free and cancer-specific survival in patients with renal cell carcinoma (RCC) using clinical, surgical, and pathologic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncologyclive_2014

    LENT Prognostic Score for Malignant Pleural Effusion

    The LENT Prognostic Score for Malignant Pleural Effusion is indicated for bedside clinical practice to support Predicts survival in patients with malignant pleural effusion using clinical and laboratory parameters to help inform treatment decisions and prognosis discussions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2016

    Lung Cancer TNM Staging (8th Edition)

    The Lung Cancer TNM Staging (8th Edition) is indicated for bedside clinical practice to support IASLC 8th edition TNM stage grouping for non-small cell lung cancer.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2005

    Mekhail Extension of the Motzer Score

    The Mekhail Extension of the Motzer Score is indicated for bedside clinical practice to support Predicts survival of metastatic renal cell carcinoma, more accurately than the original Motzer Score by incorporating additional prognostic factors. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2009

    Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival

    The Metroticket Calculator for Hepatocellular Carcinoma (HCC) Survival is indicated for bedside clinical practice to support Predicts 3 and 5-year survival after liver transplantation for patients with hepatocellular carcinoma (HCC), especially those not meeting Milan Criteria. Uses tumor size, number, and vascular invasion status.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1989

    Mirels' Criteria for Prophylactic Fixation

    The Mirels' Criteria for Prophylactic Fixation is indicated for bedside clinical practice to support Predicts risk of pathologic fracture in patients with long bone metastasis to guide prophylactic fixation decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyModified

    Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes

    The Modified Glasgow Prognostic Score (mGPS) for Cancer Outcomes is indicated for bedside clinical practice to support Provides improved cancer prognosis over the original Glasgow Prognostic Score, based on serum biomarkers (CRP and albumin) reflecting systemic inflammation and nutritional status. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2010

    Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

    The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) is indicated for bedside clinical practice to support Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC)

    The Memorial Sloan-Kettering Cancer Center (MSKCC/Motzer) Score for Metastatic Renal Cell Carcinoma (RCC) is indicated for bedside clinical practice to support Predicts survival based on clinical and laboratory data in metastatic RCC patients. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology5.0

    CTCAE Neutropenia Grade

    The CTCAE Neutropenia Grade is indicated for bedside clinical practice to support CTCAE neutropenia grading from the absolute neutrophil count (ANC): Grade 1 (<LLN-1500), Grade 2 (<1500-1000), Grade 3 (<1000-500), Grade 4 (<500 /mm³). Standard oncology toxicity grading for chemotherapy decisions and growth-factor support.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1982

    Nottingham Prognostic Index (NPI)

    The Nottingham Prognostic Index (NPI) is indicated for bedside clinical practice to support Nottingham Prognostic Index (Haybittle 1982) for primary breast cancer: NPI = 0.2 × tumor size (cm) + lymph-node stage (1-3) + histologic grade (1-3). Bands: ≤2.4 excellent, 2.41-3.4 good, 3.41-4.4 moderate, 4.41-5.4 poor, >5.4 very poor. Implemented from the published paper (AGPL source repo not copied).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2021

    Pack-Years — Smoking Burden / Lung Screening

    The Pack-Years — Smoking Burden / Lung Screening is indicated for bedside clinical practice to support Pack-years quantify lifetime smoking exposure: (cigarettes per day / 20) x years smoked. >=20 pack-years is the USPSTF 2021 lung-cancer screening threshold (ages 50-80).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology1999

    PaP Score — Palliative Prognostic Score

    The PaP Score — Palliative Prognostic Score is indicated for bedside clinical practice to support The PaP score estimates 30-day survival probability in advanced solid-tumor patients from 6 variables (dyspnea, anorexia, KPS, clinician prediction, WBC, lymphocyte %). Total 0-17.5.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologyFDA label

    Pegfilgrastim Dosing (per Label)

    The Pegfilgrastim Dosing (per Label) is indicated for bedside clinical practice to support Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • OncologySugarbaker

    Peritoneal Cancer Index (PCI)

    The Peritoneal Cancer Index (PCI) is indicated for bedside clinical practice to support Peritoneal Cancer Index (Sugarbaker): 13 abdominopelvic regions each scored by largest lesion — LS-0 none, LS-1 <0.5 cm, LS-2 0.5-5 cm, LS-3 >5 cm or confluence; total 0-39. Higher = greater tumor burden; guides cytoreduction/HIPEC decisions.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology

    PET Total Lesion Glycolysis (TLG)

    The PET Total Lesion Glycolysis (TLG) is indicated for bedside clinical practice to support Total lesion glycolysis: metabolic tumor volume multiplied by mean SUV. Prognostic PET metric in oncology.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2013

    Prognostic Index for Cancer Outcomes

    The Prognostic Index for Cancer Outcomes is indicated for bedside clinical practice to support Predicts cancer mortality from serum biomarkers using C-reactive protein (CRP) and white blood cell (WBC) count. This simple two-parameter scoring system provides risk stratification for cancer patients and helps guide prognostic discussions and clinical decision-making across multiple cancer types.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2018

    PROMISE Score for Malignant Pleural Effusion

    The PROMISE Score for Malignant Pleural Effusion is indicated for bedside clinical practice to support Predicts 3-month mortality in patients with malignant pleural effusion using clinical and biological parameters. This validated prognostic tool combines patient characteristics, performance status, laboratory values, and treatment history to provide accurate risk stratification and guide clinical decision-making for patients with malignant pleural effusion.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2012

    Prostate Tumor Volume & Density

    The Prostate Tumor Volume & Density is indicated for bedside clinical practice to support Calculates prostate volume using ellipsoid formula and PSA density to help distinguish between benign prostatic hyperplasia (BPH) and prostate cancer. This tool assists in biopsy decision-making, risk stratification, and treatment planning for patients with elevated PSA levels.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2019

    PSA Doubling Time (PSADT) Calculator

    The PSA Doubling Time (PSADT) Calculator is indicated for bedside clinical practice to support Calculates PSA doubling rate in prostate cancer patients with biochemical recurrence after treatment. This prognostic tool correlates with survival and helps guide treatment decisions for salvage therapy, imaging studies, and castration-resistant disease management. Uses longitudinal PSA measurements to determine the rate of PSA increase over time.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2015

    R-ISS

    The R-ISS is indicated for bedside clinical practice to support Revised International Staging System for multiple myeloma.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2010

    Radiation Pneumonitis Dose Constraints

    The Radiation Pneumonitis Dose Constraints is indicated for bedside clinical practice to support QUANTEC-based lung dose constraint check: mean lung dose and V20 vs symptomatic pneumonitis risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2010

    Spinal Instability Neoplastic Score (SINS)

    The Spinal Instability Neoplastic Score (SINS) is indicated for bedside clinical practice to support Spinal Instability Neoplastic Score (SINS): quantifies spinal instability in patients with spinal metastases across 6 components (location, pain, bone lesion, alignment, vertebral collapse, posterolateral involvement). Total 0-18; higher scores indicate greater instability and need for surgical consultation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
  • Oncology2005

    UCSF-CAPRA Prostate Cancer Risk Score

    The UCSF-CAPRA Prostate Cancer Risk Score is indicated for bedside clinical practice to support UCSF Cancer of the Prostate Risk Assessment (CAPRA, Cooperberg 2005): 0-10 point preoperative score predicting prostate cancer recurrence/ progression risk from PSA, Gleason pattern, clinical stage, age, and percent positive biopsy cores. 0-2 low, 3-5 intermediate, 6-10 high risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

    Calculate Score→
D
Dexamed|دگزامد

ماشین‌حساب‌های بالینی و ابزارهای تصمیم‌یار پزشکی هوشمند برای کادر درمان و دانشجویان علوم پزشکی.

ابزارهای بالینی

  • همه ماشین‌حساب‌های پزشکی
  • ماشین‌حساب‌های برگزیده من
  • صفحه اصلی پلتفرم دگزامد

پلتفرم

  • سامانه بین‌المللی DexaMed AI
  • ورود به پنل مدیریت
  • درباره ماشین‌حساب‌ها

سلب مسئولیت پزشکی

ماشین‌حساب‌های دگزامد صرفاً ابزار کمک‌تصمیم بالینی هستند و جایگزین قضاوت تخصصی و معاینه پزشک معالج محسوب نمی‌شوند.

© 2026 دگزامد — تمام حقوق محفوظ است.

مجموعه ماشین‌حساب‌ها و امتیازهای تشخیصی-بالینی دگزامد